The role of noggin in regulation of high glucose-induced apoptosis and insulin secretion in INS-1 rat beta cells

Document Type: Original Article

Authors

1 Department of Endocrinology, the Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, Heilongjiang, China, 161000

2 Department of General Surgery, the Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, Heilongjiang, China, 161000

3 Department of Anatomy, Qiqihar Medical University, Qiqihar, Heilongjiang, China, 161006

Abstract

Objective(s):The purpose of this study was to investigate the effects of Noggin on high glucose-induced apoptosis and insulin secretion in pancreatic beta cells.
Materials and Methods: Different concentrations of glucose were used to examine their effects on INS-1 rat beta cells in vitro. When specific siRNA targeting Noggin and recombinant Noggin were added, apoptosis and insulin secretion were measured, respectively to determine their effects in INS-1 cells.
Results: Glucose stimulated the expression of Noggin in a dose-dependent manner. Knockdown of Noggin further increased apoptosis and reduced insulin secretion when INS-1 cells were exposed to high glucose. Conversely, administration of recombinant Noggin significantly reduced apoptotic cell number, and promoted insulin secretion. Finally, treatment with inhibitor of Smad phosphorylation exerted similar effects on cell apoptosis and insulin production to Noggin administration in glucose-treated INS-1 cells.
Conclusion: Our findings indicate that Noggin inhibits apoptosis and promotes insulin secretion in pancreatic beta cells through the inhibition of Smad signaling. Gene therapy of delivering Noggin may facilitate the treatment for patients with type 2 diabetes mellitus.

Keywords


1. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives. Nat Rev Endocrinol 2011; 8:228-236.

2. Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents.  J Pediatr 2005; 146:693-700.

3. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87:4-14.

4. Buchanan TA. Pancreatic B-cell defects in gestational diabetes: implications for the pathogenesis and prevention of type 2 diabetes. J Clin Endocrinol Metab 2001; 86:989-993.

5. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32:193-203.

6. Aronoff SL, Berkowitz K, Shreiner B, Want L. Glucose metabolism and regulation: beyond insulin and glucagon. Diabetes Spectr 2004; 17:183-1890.

7. Van den Berghe G. How does blood glucose control with insulin save lives in intensive care? J Clin Invest 2004; 114:1187.

8. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001; 414:799-806.

9. Kaung HC. Effect of glucose on beta cell proliferation and population size in organ culture of foetal and neonatal rat pancreases. J Embryol Exp Morphol 1983; 75:303-312.

10. Like A, Chick W. Studies in the diabetic mutant mouse: I. Light microscopy and radioautography of pancreatic islets. Diabetologia 1970; 6:207-215.

11. Robertson RP, Harmon J, Tran PO, Tanaka Y, Takahashi H. Glucose toxicity in β-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 2003; 52:581-587.

12. Zhang Z, Liew CW, Handy DE, Zhang Y, Leopold JA, Hu J, et al. High glucose inhibits glucose-6-phosphate dehydrogenase, leading to increased oxidative stress and β-cell apoptosis. FASEB J 2010; 24:1497-1505.

13. Kim W-H, Lee JW, Suh YH, Hong SH, Choi JS, Lim JH, et al. Exposure to chronic high glucose induces β-Cell apoptosis through decreased interaction of glucokinase with mitochondria downregulation of glucokinase in pancreatic β-Cells. Diabetes 2005; 54:2602-2611.

14. McMahon JA, Takada S, Zimmerman LB, Fan C-M, Harland RM, McMahon AP. Noggin-mediated antagonism of BMP signaling is required for growth and patterning of the neural tube and somite. Genes Dev 1998; 12:1438-1452.

15. Canalis E, Economides AN, Gazzerro E. Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 2003; 24:218-235.

16. Bruun C, Christensen GL, Jacobsen ML, Kanstrup MB, Jensen PR, Fjordvang H, et al. Inhibition of beta cell growth and function by bone morphogenetic proteins. Diabetologia 2014; 57:2546-2554.

17. Chen C, Grzegorzewski KJ, Barash S, Zhao Q, Schneider H, Wang Q, et al. An integrated functional genomics screening program reveals a role for BMP-9 in glucose homeostasis. Nat Biotechnol 2003; 21:294-301.

18. El-Gohary Y, Tulachan S, Wiersch J, Guo P, Welsh C, Prasadan K, et al. A smad signaling network regulates islet cell proliferation. Diabetes 2014; 63:224-236.

19. El-Gohary Y, Tulachan S, Guo P, Welsh C, Wiersch J, Prasadan K, et al. Smad signaling pathways regulate pancreatic endocrine development. Dev Biol 2013; 378:83-93.

20. He F, Xiong W, Wang Y, Matsui M, Yu X, Chai Y, et al. Modulation of BMP signaling by Noggin is required for the maintenance of palatal epithelial integrity during palatogenesis. Dev Biol 2010; 347:109-121.

21. Moynihan KA, Grimm AA, Plueger MM, Bernal-Mizrachi E, Ford E, Cras-Méneur C, et al. Increased dosage of mammalian Sir2 in pancreatic β cells enhances glucose-stimulated insulin secretion in mice. Cell Metab 2005; 2:105-117.

22. Robertson RP, Harmon J, Tran POT, Poitout V. β-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 2004; 53:S119-S124.

23. Wallace M, Whelan H, Brennan L. Metabolomic analysis of pancreatic beta cells following exposure to high glucose. Biochim Biophys Acta 2013; 1830:2583-2590.

24. Matschinsky FM. Glucokinase as glucose sensor and metabolic signal generator in pancreatic β-cells and hepatocytes. Diabetes 1990; 39:647-652.

25. Donath MY, Ehses JA, Maedler K, Schumann DM, Ellingsgaard H, Eppler E, et al. Mechanisms of beta-Cell Death in Type 2 Diabetes. Diabetes. 2005; 54:S108-113.

26. Leonardi O, Mints G, Hussain MA. Beta-cell apoptosis in the pathogenesis of human type 2 diabetes mellitus. Eur J Endocrinol 2003; 149:99-102.

27. Schuster N, Krieglstein K. Mechanisms of TGF-β-mediated apoptosis. Cell Tissue Res 2002; 307:1-14.

28. Smart NG, Apelqvist ÅA, Gu X, Harmon EB, Topper JN, MacDonald RJ, et al. Conditional expression of Smad7 in pancreatic β cells disrupts TGF-β signaling and induces reversible diabetes mellitus. PLoS Biol 2006; 4:e39.

29. Gannon M. BuMP-ing up insulin secretion by pancreatic β cells. Cell Metab 2007; 5:157-159.

30. Goulley J, Dahl U, Baeza N, Mishina Y, Edlund H. BMP4-BMPR1A signaling in β cells is required for and augments glucose-stimulated insulin secretion. Cell Metab 2007; 5:207-219.

31. Alberti K, Zimmet Pf. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 4:539-553.

32. Heldin C-H, Miyazono K, Ten Dijke P. TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature 1997; 390:465-471.

33. Xu X, Browning VL, Odorico JS. Activin, BMP and FGF pathways cooperate to promote endoderm and pancreatic lineage cell differentiation from human embryonic stem cells. Mech Dev 2011; 128:412-427.

34. Mfopou JK, Chen B, Mateizel I, Sermon K, Bouwens L. Noggin, retinoids, and fibroblast growth factor regulate hepatic or pancreatic fate of human embryonic stem cells. Gastroenterology 2010; 138:2233-2245.e14.